Portal de Periódicos da CAPES

Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy

1997; Wiley; Volume: 166; Issue: 10 Linguagem: Inglês

10.5694/j.1326-5377.1997.tb123243.x

1326-5377

Michael Michael, James F. Bishop, Jennifer Smith, Guy C. Toner, John A. Levi, David R. Bell, John Zalcberg, Michael Friedlander, Ian Olver,

Breast Cancer Treatment Studies

Objective To determine the efficacy and safety of paclitaxel given as a three-hour infusion in patients with metastatic breast cancer which had progressed despite hormonal therapy and/or chemotherapy. Design and setting Multicentre phase II trial undertaken in five major centres or hospitals in Sydney, Melbourne and Adelaide. Patients and methods 50 patients with clinically or radiologically measurable or evaluable metastatic breast cancer recruited between March and July 1993. All had received prior chemotherapy, with subsequent disease progression. Intervention Paclitaxel (Anzatax, Faulding) was given at a dose of 175 mg/m2 intravenously over three hours every three weeks for up to nine courses. Main outcome measures Response rate (partial or complete); duration of progression-free survival; duration of survival; and adverse reactions. Results Patients had a median age of 51 years; 62% had received at least two prior drug regimens for metastatic breast cancer and 48% had anthracycline-resistant tumours. A median of six paclitaxel courses was given per patient. Overall response rate was 18% (95% confidence interval [95% CI], 9%-31%), with complete responses in four patients (8%). In patients with anthracycline-resistant tumours, response rate was 25% (95% CI, 10%-47%). Response was not influenced by extent of prior treatment. Estimated median progression-free survival was 4.1 months (95% CI, 3.2–6.0 months) and estimated median survival was 8.3 months (95% CI, 6.2–10.3 months). Treatment was well tolerated, with neutropenia the major toxic effect. Conclusions Paclitaxel (three-hour infusion) has significant activity in heavily pretreated patients with metastatic breast cancer, including anthracycline-resistant tumours.